CliffBio
small molecule

COMPLERA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

Loss of exclusivityJanuary 2033latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameCOMPLERA
Active ingredientEMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
Strength200MG;EQ 25MG BASE;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2011
Marketing statusRX

Listed patents

PatentExpiresType
10857102January 2033product

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

COMPLERA patent cliff — loss of exclusivity January 2033 | CliffBio